Introduction Secukinumab, a fully human monoclonal antibody, targets interleukin-17A (IL-17A), a pro-inflammatory cytokine implicated in giant cell arteritis (GCA) (1). This Phase III trial evaluates the efficacy and safety of secukinumab 300 mg administered subcutaneously (SC) over 52 weeks, alongside a 26-week prednisone taper, in approximately 2
16 Reached
ACC, AHA and ESC Recommendations for Heart Failure Management
2323 Reached29 Comments2 Likes
Catheter Ablation for Atrial Fibrillation with HF
691 Reached
Woman in ED with Abdominal Pain and Shortness of Breath
489 Reached1 Likes
Rare Case of Isolated fracture
448 Reached1 Likes
Female with History of Amenorrhoea
3094 Reached10 Comments11 Likes